Molecular Predictive Testing in Ocular Melanoma
Description: Project Narrative In previous funding periods of this grant, we developed a highly innovative gene expression profile-based prognostic test for uveal melanoma that is now the widely used first-in-class industry standard in the field. We have since discovered new prognostically significant mutations in BAP1 and SF3B1 and a new mRNA biomarker (PRAME) that will set a new standard for prognostic accuracy, while also guiding the choice of systemic therapy. In this competitive renewal, we propose a landmark prospective 28-center study to optimize and validate these new biomarkers, and to develop a ground breaking new prognostic test based on circulating exosomal microRNA profiling performed on routine blood samples, which will greatly expand the number of patients with uveal melanocytic tumors who will benefit from personalized genomic medicine.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2006-07-01
End date: 2023-03-31
Investigator: ZELIA MARIA CORREA (lead)
Institutions: University of Miami, UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 85
Funder award ID: R01CA125970
OpenAlex ID: G4039377828